The Simoa NPTX2 Advantage PLUS Assay is designed for researchers investigating the relationship between synaptic health, cognitive function, and neurodegenerative disease progression. By enabling quantitative measurement of NPTX2 in human samples, the assay supports studies focused on cognitive trajectory, synaptic dysfunction, and disease-related changes in neuronal connectivity. NPTX2 is particularly valuable in Alzheimer’s disease and other neurodegenerative disorders where declining synaptic integrity is closely linked to worsening cognition. Researchers can use NPTX2 to complement traditional cognitive assessments, evaluate biomarker changes over time, and gain deeper insight into the biological mechanisms underlying cognitive resilience and decline. Additionally, NPTX2 can be measured alongside other synaptic biomarkers, including SNAP-25 and PSD-95, to provide a more comprehensive view of synaptic function and neurodegenerative disease biology.
A Distinctive Marker of Synaptic Integrity
NPTX2 is the only biomarker within the Quanterix neurology portfolio that decreases as cognitive function declines, providing researchers with a unique perspective on synaptic health and disease progression.
Automated and Scalable Workflow
Powered by the fully automated HD-X platform, the assay delivers precise, reproducible results with the scalability required for longitudinal studies and large clinical research programs.
Complementary to SNAP-25 and PSD-95
Expand synaptic biomarker investigations by combining NPTX2 with SNAP-25 and PSD-95. Published studies have evaluated the SNAP-25:NPTX2 ratio as a predictor of cognitive decline, making these assays highly complementary for synaptic research.
The Simoa NPTX2 Advantage PLUS Assay is designed for use on the Quanterix HD-X™ platform and compatible with the Quanterix S-X™ platform, enabling fully automated, high-sensitivity measurement of NPTX2.
Simoa® NPTX2 Advantage PLUS Assay Performance
Note: While validation studies were conducted in CSF; serum, and plasma, current clinical evidence suggests the strongest biological utility of NPTX2 is in CSF applications.
The Simoa® NPTX2 Advantage PLUS Assay Kit includes all reagents and controls necessary to perform 96 tests, ensuring consistency and reliability in every run.
Researchers studying synaptic dysfunction, cognitive decline, and neurodegenerative disease can pair the Simoa® NPTX2 Advantage PLUS Assay with the Simoa® SNAP-25 Advantage PLUS Assay and Simoa® PSD-95 Advantage PLUS Assay to gain a more comprehensive understanding of synaptic biology. Together, these biomarkers provide complementary insights into neuronal communication, synaptic integrity, and cognitive trajectory. Studies investigating the SNAP-25:NPTX2 ratio suggest additional utility for understanding cognitive decline and disease progression, making NPTX2 a valuable addition to synaptic biomarker panels.
Neurology
There is no excerpt because this is a protected post.
Realizing the promise of multimodal diagnostics raises important questions: How should we think about integrating these different sources of information? Where can multimodal approaches add the most value? And what…
Disease is complex, dynamic, and heterogeneous, and no one biomarker modality can capture every dimension of that complexity. Liquid and tissue biomarkers answer different biological questions, each providing a distinct…
Cancer
Lung cancer is a formidable foe. Globally, it is the leading cause of cancer-related deaths in men and women, with non-small lung cancer (NSCLC) representing more than 80% of all…
The promise of proteomics lies in its ability to illuminate disease biology at scale, transform translational research, and guide the development of precision diagnostics and targeted therapies. While genomic technologies…
Translating proteomic discovery into clinical action requires more than scale, it demands precision, reproducibility, and quantitative clarity. The Quanterix Simoa® digital immunoassay technology was purpose-built to meet the demands of…
Neurology
Poster Background Developing effective therapies for glioblastoma (GBM) relies on robust preclinical animal models that enable detailed investigation of tumor biology, discovery of therapeutic targets, and evaluation of new treatment…
Oncology
Poster Background Ultrahigh-Plex Single-cell Spatial Phenotyping has revealed valuable insights into the tumor immune microenvironment (TiME) for biomarker discovery and stratification of clinical responses. Metabolic reprogramming is a key hallmark…
Neurology
Alzheimer’s Research and Therapy | August 26, 2024 Sampani K, Ness S, Tuz-Zahra F, Aytan N, Spurlock EE, Alluri S, Chen X, Siegel NH, Alosco ML, Xia W, Tripodis Y,…
Neurology
Poster The intersection of new therapeutic options for Alzheimer’s disease (AD), the emergence of accurate blood-based tests for AD, and the anticipated health system log jam for confirmatory diagnostic testing…
Neurology
Alzheimer’s & Dementia | August 3, 2024 Verberk IMW, Jutte J, Kingma MY, Vigneswaran S, Gouda MMTEE, van Engelen MP, Alcolea D, Arranz J, Fortea J, Lleó A, Chevalier C,…
Neurology
Journal of Lipid Research | August 2, 2024 Becktel DA, Frye JB, Le EH, Whitman SA, Schnellmann RG, Morrison HW, Doyle KP. J Lipid Res. 2024 https://doi.org/10.1016/j.jlr.2024.100614 Abstract Ischemic stroke…
Molecular Barcoding Kit Now Available Globally; TIME and high-plex ADC panels confirmed for Q4 shipment; Accelerator Laboratory Services open custom ADC panel development BILLERICA, Mass.–September 25, 2026–Quanterix Corporation (NASDAQ: QTRX)…
BILLERICA, Mass.–September 14, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that accomplished physician executive Dr. Yuri Fesko has been appointed Chief Medical Officer of…
Reports $32.9 million in revenue and $96.9 million of cash and marketable securities Company accelerating initiatives to drive commercial effectiveness Revises financial outlook for 2026 and extends date for attaining…
Brings 20 years of senior commercial leadership in healthcare and IT, including GE Healthcare and Exact Sciences BILLERICA, Mass.–August 10, 2026–Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker…
BILLERICA, Mass. – August 6, 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that senior management will participate in the Canaccord Genuity Capital…
BILLERICA, Mass. – August 4 2026 – Quanterix Corporation (Nasdaq: QTRX), a global leader in precision biomarker science, today announced that it will host a conference call on Monday, August…
BILLERICA, Mass. – June 16, 2026 – Quanterix Corporation (“Quanterix” or the “Company”) (NASDAQ: QTRX), a company transforming healthcare by accelerating biomarker breakthroughs from discovery to diagnostics, today announced that on June 15,…
Explore our library of resources, posts and materials.
Contact our team for customer support, distributor inquiries, or general questions.
